GCP Clinical Research — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$105,984	16
2024	Research	$2,569,435	25
2023	Research	$546,687	84
2022	Research	$475,139	36
2021	Research	$340,721	2
2020	Research	$264,679	2
2019	Research	$15,508	1

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $2,424,051 3 payments
Horizon Therapeutics plc $1,473,188 13 payments
Pfizer Inc. $354,586 37 payments
Sanofi US Services Inc. $55,338 4 payments
Sumitomo Pharma America, Inc. $8,782 41 payments
Arena Pharmaceuticals, Inc. $2,208 68 payments

Studies the money was for Research payments · program years 2019–2025

P4 Uncontrolled Gout FORWARD II $2,422,798 2 payments
Infusion Duration Study to Assess Tolerability of Pegloticase Administered With A Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate $721,214 4 payments
A Phase 1B Randomized Doubleblind Placebocontrolled Multicenter Study to Evaluate the Efficacy Safety and Pharmacokinetics of Oral Pf07054894 in Adult Participants Aged 1875 Years With Moderate to Severe Ulcerative Colitis $354,586 37 payments
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa? (Pegloticase) (Mirror Randomized Controlled Trial [RCT]) $265,577 2 payments
A Randomized Double-Blind Placebo-Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa (Pegloticase) (Mirror Randomized Controlled Trial RCT ) $147,729 1 payment
A Phase 4, Open-Label Study of Krystexxa (Pegloticase) Co-Administered With Methotrexate (MTX) in Patients With Uncontrolled Gout $130,457 1 payment
A Phase 1B, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects With Uncontrolled Gout Receiving Methotrexate $100,375 1 payment
A Phase 4, Open-Label Study of Krystexxa? (Pegloticase) Co-Administered With Methotrexate (MTX) in Patients With Uncontrolled Gout $56,979 1 payment
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype $55,338 4 payments
A Phase 4, Multicenter, Open-Label, Efficacy and Safety Trial of Pegloticase and Methotrexate Co-Administered in Patients With Uncontrolled Gout Who Have Previously Received Pegloticase Monotherapy But Did Not Maintain A Serum Uric Acid Response $35,349 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.